Skip to main content
TipRanks
Go Ultimate75% OFF

Alkem Laboratories Ltd. (ALKEM) AI Stock Analysis

2 Followers
IN:ALKEM

Alkem Laboratories Ltd.

(NSE:ALKEM)

Select Model
Rating:66Neutral
Price Target:INR 5,778.00â–²(12.30% Upside)
Action:reiterated
Date:08/29/26

The score is primarily driven by strong financial performance (steady growth, solid profitability, and low leverage), partially offset by weaker cash conversion. Technical indicators are currently bearish/soft (below key moving averages with negative MACD), and valuation support is limited given the ~29.7 P/E and ~1% dividend yield.

Positive Factors
Revenue Growth and ProfitabilitySteady revenue expansion, including a strong latest-year pickup, alongside healthy operating and net margins indicates broad commercial traction and an established earnings base. This supports continued investment across the portfolio and distribution network, although future growth still depends on sustaining execution.
Negative Factors
Weak Cash ConversionWeak conversion of accounting profit into cash can limit the amount available for reinvestment and shareholder distributions, even when reported earnings are healthy. Continued working-capital or reinvestment demands could therefore reduce financial flexibility and make earnings less immediately cash-backed.

Alkem Laboratories Ltd. (ALKEM) vs. iShares MSCI India ETF (INDA)

-20%-15%-10%-5%0%5%IN:ALKEM-7.69%INDA-4.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 613.07B
Dividend Yield
1.03%
Average Volume (3M)
14.56K
Price to Earnings (P/E)
29.8
Beta (1Y)
0.53
Revenue Growth
12.54%
EPS Growth
-12.62%
Country
India
Employees
19,346
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Alkem Laboratories Ltd. Business Overview & Revenue Model

Company Description

Alkem Laboratories Ltd. functions as a pharmaceutical enterprise, engaged in the research, manufacturing, and worldwide distribution of both medicinal and nutritional products. Its comprehensive offerings encompass a variety of branded and generic dr...

How the Company Makes Money

Alkem makes money primarily by selling pharmaceutical products, with revenues driven by (1) domestic sales in India and (2) international sales through exports and overseas market presence. Its core revenue model is product-led: it manufactures finis...

Alkem Laboratories Ltd. Financial Statement Overview

Summary

Strong overall fundamentals supported by steady revenue expansion, solid profitability, and a conservatively positioned balance sheet with low leverage and healthy (though moderating) ROE. The main offset is weaker cash conversion, with free cash flow not consistently keeping pace with net income.

Income Statement

78Positive

Balance Sheet

82Very Positive

Cash Flow

70Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue150.81B147.12B128.05B124.39B114.40B105.12B
Gross Profit90.49B96.19B79.47B74.07B64.58B62.29B
EBITDA32.91B34.14B29.71B24.18B17.09B21.89B
Net Income21.57B23.02B21.65B17.96B9.84B16.46B
Balance Sheet
Total Assets0208.73B176.91B155.75B137.57B140.69B
Cash, Cash Equivalents and Short-Term Investments40.61B40.65B37.78B42.70B11.43B13.13B
Total Debt020.47B13.81B14.18B13.97B26.68B
Total Liabilities-143.49B65.24B52.57B48.60B43.22B52.22B
Stockholders Equity143.49B138.20B119.85B103.12B90.45B86.38B
Cash Flow
Free Cash Flow4.40B13.46B12.37B16.89B14.50B7.72B
Operating Cash Flow8.37B19.63B19.13B19.48B16.82B11.11B
Investing Cash Flow-15.68B-16.67B-12.99B-10.09B1.13B-14.35B
Financing Cash Flow4.63B-5.03B-8.11B-11.45B-17.61B3.80B

Alkem Laboratories Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price5145.00

Price Trends

50DMA5196.02Negative
100DMA5354.87Negative
200DMA5395.98Negative

Market Momentum

MACD4.35Positive
RSI47.16Neutral
STOCH19.74Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALKEM, the sentiment is Negative. The current price of 5145.00 is below the 20-day moving average (MA) of 5164.64, below the 50-day MA of 5196.02, and below the 200-day MA of 5395.98, indicating a bearish trend. The MACD of 4.35 indicates Positive momentum. The RSI at 47.16 is Neutral, neither overbought nor oversold. The STOCH value of 19.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALKEM.

Alkem Laboratories Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:ALKEM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:AUROPHARMAIN:AUROPHARMA80OutperformINR 1.04T26.18―0.39%13.53%17.04%
IN:TORNTPHARMIN:TORNTPHARM69NeutralINR 1.76T75.54―0.32%42.06%-3.48%
IN:MANKINDIN:MANKIND67NeutralINR 1.09T48.39―0.04%13.27%27.32%
IN:ALKEMIN:ALKEM66NeutralINR 615.16B29.82―1.03%12.54%-12.62%
IN:SUNPHARMAIN:SUNPHARMA64NeutralINR 4.57T41.58―0.84%12.13%4.94%
IN:DRREDDYIN:DRREDDY63NeutralINR 1.17T41.69―0.57%-3.60%-52.23%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%20%40%IN:ALKEMIN:AUROPHARMAIN:DRREDDYIN:MANKINDIN:SUNPHARMAIN:TORNTPHARMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:ALKEM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:ALKEMAlkem Laboratories Ltd.5145.00-500.70-8.87%
IN:AUROPHARMAAurobindo Pharma Ltd1807.00606.2650.49%
IN:DRREDDYDr. Reddy's Laboratories Ltd.1398.00161.2913.04%
IN:MANKINDMankind Pharma Ltd.2630.00387.0017.25%
IN:SUNPHARMASun Pharmaceutical Industries Limited1903.00139.317.90%
IN:TORNTPHARMTorrent Pharmaceuticals Ltd4616.00958.7426.21%

Alkem Laboratories Ltd. Corporate Events

Alkem Laboratories Incorporates Saudi Arabian Pharmaceutical Joint Venture

Nov 8, 2026

Alkem Laboratories, a pharmaceutical company focused on medicines and nutraceutical products, has incorporated Alkem Pharma Company, a limited liability joint venture in Saudi Arabia. The venture broadens the company’s international market focus and...

Alkem Orders Forensic Audit After Alleged Employee Fund Misuse

Oct 21, 2026

Alkem Laboratories Ltd. has initiated a forensic audit after detecting a recent incident involving alleged misappropriation of funds by a former employee, as approved by its Audit Committee on October 21, 2026. The move reflects the company’s effort...

Alkem Laboratories Strengthens Leadership With Senior Management Appointment

Sep 15, 2026

Alkem Laboratories has appointed Dr. Shubhadeep Sinha to a senior management role effective September 15, 2026, strengthening its leadership team. Dr. Sinha brings over 25 years of experience across clinical development, medical affairs, pharmacovigi...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 29, 2026